



Registration & Breakfast	Co-hosted by:
08:00 - 09:00 Satellite Sessions	14:00 - 16:00 Pharma Leader Forums
Keynote Sessions	Co-hosted by: 16:00 - 17:40
Satellite Sessions	CEO Forums
Morning Break	Networking Drinks
10:00 - 10:30 Satellite Sessions	17:40 - 17:45 Networking Break
CEO Forums	
10:30 - 11:00 CEO Forums	
Pharma Leader Forums	
10:30 - 11:00 Pharma Leader Forums	
Co-hosted by:	
11:00 - 12:50 CEO Forums	
Co-hosted by:	
11:00 - 12:50 Pharma Leader Forums	
Lunch Break	
12:50 - 14:00 Networking Break	
Co-hosted by:	
14:00 - 16:00 CEO Forums	

SCHEDULEFORUMS & WORKSHOPS (SEP 11TH) -

TIME	SATELLITE SESSIONS	CEO FORUMS	PHARMA LEADER FORUMS	NETWORKING BREAK
08:00	08:00 - Registration & Breakfast			
09:00	09:00 - Keynote Sessions			
10:00	10:00 - Morning Break	10:30 - CEO Forums	10:30 - Pharma Leader Forums	
11:00		11:00 - Co-hosted by:	11:00 - Co-hosted by:	
12:00				12:50 - Lunch Break
14:00		14:00 - Co-hosted by:	14:00 - Co-hosted by:	
16:00		16:00 - Co-hosted by:		
17:00				17:40 - Networking Drinks





Registration & Breakfast 08:00 - 09:00 Satellite Sessions	Close of Conference Day 2 15:40 - 15:45 Networking Break
Keynote Sessions	
Satellite Sessions	
Morning Break	
10:00 - 10:30 Satellite Sessions	
CEO Forums	
10:30 - 11:10 CEO Forums	
Workshops	
10:30 - 11:10 Workshops	
Co-hosted by:	
11:10 - 12:50 CEO Forums	
Co-hosted by:	
11:10 - 12:50 Workshops	
Lunch Break	
12:50 - 14:00 Networking Break	
Co-hosted by:	
14:00 - 15:40 Workshops	



TIME	SATELLITE SESSIONS	CEO FORUMS	WORKSHOPS	NETWORKING BREAK
08:00	08:00 - Registration & Breakfast			
09:00	09:00 - Keynote Sessions			
10:00	10:00 - Morning Break	10:30 - CEO Forums	10:30 - Workshops	
11:00		11:10 - Co-hosted by:	11:10 - Co-hosted by:	
12:00				12:50 - Lunch Break
14:00			14:00 - Co-hosted by:	
15:00				15:40 - Close of Conference Day 2

SESSIONS

DAY 1 - WEDNESDAY, 11TH SEPTEMBER - 11/09/2024

Connecting Innovators with Strategic Knowledge & Capital
September 11th - 12th, 2024
Hynes Convention Centre, Boston, MA, USA

Registration & Breakfast

08:00 - 09:00 Registration & Breakfast

LSX WELCOME ADDRESS

09:00 - 09:10 MEDTECH LEADERS

Participants

Caitlin McNally - Conference Director- Medtech Lead, LSX

Sustained Success - A Holistic Review of MedTech in 2024

09:10 - 09:50 MEDTECH LEADERS

Medical device companies stabilized in 2023 after overcoming challenges from the three-year pandemic. Industry leaders reported positive Q3 2023 earnings and a strong operating environment. With an uptick in deals at the end of 2023, and early 2024, the medtech sector outlook remains positive, with valuations exceeding pre-pandemic levels. Analysts anticipate continuous growth and margin improvement driven by macro trends, including an aging population and technological advances. Amid peaking investor interest and new disruptors entering the space, medtech companies must prioritize innovation for sustained resilience and growth. This panel reviews 2024 so far and anticipates what the sector will bring in 2025.

- What is the current M&A appetite
- Current financial landscape for medtech
- · Which medtech fields are taking off
- Innovation update for Tier 1 medtech who are they looking for

Participants

Joseph Smith - CSO, BD

Carla Peron - Chief Medical Officer, Philips

Dr. Trang Ly - SVP Medical Director, Insulet Corporation

Promises in Pixels - Evaluating Al's Impactful Delivery

09:50 - 10:30 MEDTECH LEADERS

Throughout 2023, considerable discourse unfolded regarding the prospective role of AI in the healthcare sector and its capacity to redefine healthcare delivery. From advancements in robotics, navigation, augmented reality, to the integration of remote sensors, digital technologies have demonstrated their capability to enhance clinical, operational, and financial outcomes. While this transformation has been evident in theoretical discussions and the emergence of pioneering medtech startups incorporating AI, a critical question persists: has the actual implementation and maturity of these technologies resulted in a sustained and disruptive impact on the healthcare industry?

- In what ways has AI propelled advancements in medtech
- What obstacles have been encountered during the implementation process
- Has the value and impact of the benefits justified the initial hype and rapid influx of funding

Participants

Susan Wood - CEO, Vida Diagnostics

Karen Holzberger - President & CEO, SpinTech MRI

Carlos Morales - VP Research & Development, DYSIS

Morning Break

10:30 - 11:00 Morning Break

Keeping The Cash Flow - Sustaining Momentum Through Maturation

11:00 - 11:50 MEDTECH LEADERS

In the midst of challenging macroeconomic conditions, medtech firms pursuing later-stage funding need to showcase robust revenue projections and tangible growth to entice investors who prioritize companies with unique revenue models. A panel of seasoned investors will delve into the strategies employed by companies, discussing innovative financial structures with strategic partners and the utilization of venture debt as a catalyst for driving sustained growth.

- What trends or strategies do investors prioritize when assessing a medtech company's revenue outlook
- How do successful medtech firms attract laterstage funding amid challenging economic conditions
- Key considerations for medtech firms utilizing venture debt as a catalyst for sustained growth

Participants

David Kereiakes - Managing Partner, Windham Venture Partners

Darshana Zaveri - Managing Partner, Catalyst Health Ventures

Rulebook Roulette - Winning Strategies For US Medtech Compliance

11:50 - 12:40 MEDTECH LEADERS

The US medtech industry stands as a global leader, attracting both domestic and international companies. However, navigating the intricate regulatory landscape in the US, especially with recent changes in digital health and AI documentation, poses a formidable challenge. A panel of industry regulatory experts gathers to discuss essential strategies for building a robust regulatory foundation.

- Understanding FDA requirements and relationship building
- Building clinical evidence and exploring expedited pathways
- Developing a robust pre-submission strategy

Participants

Karen Cross - Co-Founder & CEO, MIMOSA Diagnostics

John Konsin - CEO & Co-Founder, Prapela

Christy Sheehy-Bensinger - CEO & Founder, C-Light Technologies

Lunch Break

12:40 - 13:40 Networking Break

SESSIONS

DAY 1 — WEDNESDAY, 11TH SEPTEMBER - 11/09/2024

Connecting Innovators with Strategic Knowledge & Capital
September 11th - 12th, 2024
Hynes Convention Centre, Boston, MA, USA

Ctrl+Challenge - SaaMD Pathways and Pitfalls

13:40 - 14:40 MEDTECH LEADERS

The medical device industry has only recently started designing software-based products unrelated to traditional hardware devices. Despite their departure from conventional medical devices, Software as a Medical Device (SaMD) holds significant potential to enhance patients' quality of life, even though regulatory bodies worldwide still categorize them as medical devices. The panel will delve into the challenges of bringing software-based medical devices to the market.

- · Regulatory need to know for SaMD/SiMD
- · Commercialising SaaMD products
- Pathways for payment and coverage
- Ethical implications and security concern

Participants

Cathy Skinner - CEO, NXgenPort Inc

Kevin Stevens - Head, Global Regulatory Affairs Device, PDT, Takeda

Blake Richards - CEO, Elucid

Access Granted - Strategies For Successful Market Entry

14:40 - 15:40 MEDTECH LEADERS

The competitive medtech landscape requires organizations to not only secure 510(k) FDA clearance but also effectively communicate the clinical and economic value of their technology in the evolving landscape of value-based care. Essential strategies for success encompass showcasing value to diverse stakeholders and developing comprehensive market access plans. A panel of senior leaders in the world of market access, discuss what medtech companies need to know once they've achieved clearance or approval.

- Navigating post-market surveillance and evidence generation
- Establishing an entity in the U.S
- · Reimbursement pathways and finding distributors

Participants

Christine Horton - CEO, Visura Technologies

Nishant Doctor - CEO, Surf Therapeutics

Marc Jones - CEO, Altoida

Afternoon Break

15:40 - 16:10 Networking Break

Strategic Synergies: Scaling Through Industry Collaboration

16:10 - 16:50 MEDTECH LEADERS

In the dynamic healthcare sector, market challenges and disruptions affect both new and established players. This panel explores how industry-wide collaboration, offering disruptive solutions, can address market challenges, enhance resilience, and drive long-term growth.

- Leveraging partnerships and collaborations within the industry
- Utilising AI and how to partner with providers of
 data
- Working with healthcare providers to create 'beyond the product' solutions
- · Implications of out-sourcing needs

Participants

Debbie Lin - Venture Partner, T.Rx Capital

Kurt Haggstrom - CCO, Synchron

Ana Maiques - CEO & Co-Founder, Neuroelectrics

Jonathan Hoyt - Executive Director, Global Market Development, Olympus Corporation of the Americas

Put It On Your Pitchdeck - Meeting Investor Expectations

16:50 - 17:30 MEDTECH LEADERS

Medtech startups face challenges in fundraising due to a shortage of early-stage investors and obstacles on the path to commercialization. Despite substantial growth in venture funding for the medtech sector, there's a noticeable shift towards mid to later-stage investments, driven by reduced returns and complexities in reimbursement. Investors now prioritize ventures that combine security, innovation, and clinical success. Learn from early-stage investors about their evaluation criteria and discover effective strategies to cultivate relationships, improving the chances of securing seed or series A funding. This session explores how early-stage medtech firms can navigate the journey from initial funding to market success, aligning with investors' evolving expectations.

- · Aligning with investor expectations
- Bridging the funding to viability gap
- Building investor-attractive foundations
- Creating a strong investment proposition

Participants

Gwen Watanabe - Managing Director, H.I.G. Capital

Amy Salzhauer - Founder & Managing Partner, Good Growth Capital

Tom Miller - Founding & Managing Partner, GreyBird Ventures, LLC

CLOSE OF DAY 1 AGENDA – DRINKS RECEPTION FOLLOWED

17:30 - 17:35 Networking Break

SCHEDULEDAY 1 – WEDNESDAY, 11TH SEPTEMBER - 11/09/2024

TIME	REGISTRATION & BREAKFAST	MEDTECH LEADERS	MORNING BREAK	NETWORKING BREAK
08:00	08:00 - Registration & Breakfast			
09:00		09:00 - LSX WELCOME ADDRESS 09:10 - Sustained Success - A Holistic Review of MedTech in 2024 09:50 - Promises in Pixels - Evaluating Al's Im-		
10:00		pactful Delivery	10:30 - Morning Break	
11:00		11:00 - Keeping The Cash Flow - Sustaining Momentum Through Maturation 11:50 - Rulebook Roulette - Winning Strategies For US Medtech Compliance		
12:00				12:40 - Lunch Break
13:00		13:40 - Ctrl+Challenge – SaaMD Pathways and Pitfalls		
14:00		14:40 - Access Granted - Strategies For Successful Market Entry		
15:00				15:40 - Afternoon Break
16:00		16:10 - Strategic Synergies: Scaling Through Industry Collaboration 16:50 - Put It On Your Pitchdeck - Meeting Investor Expectations		
17:00				17:30 - CLOSE OF DAY 1 AGENDA – DRINKS RE- CEPTION FOLLOWED

SESSIONS

DAY 2 - THURSDAY 12TH SEPTEMBER - 12/09/2024

Connecting Innovators with Strategic Knowledge & Capital September 11th - 12th, 2024 Hynes Convention Centre, Boston, MA, USA

REGISTRATION & BREAKFAST

08:00 - 09:00 Registration & Breakfast

LSX WELCOME ADDRESS

09:00 - 09:10 MEDTECH LEADERS

Bold Moves and Buyouts: The Medtech 2025 M&A Blueprint

09:10 - 09:50 MEDTECH LEADERS

Following an industry rebound in 2023, the sector anticipates sustained positive momentum through 2025. A panel of senior executives from Tier 1 medtech examine current acquisition trends in 2024, offering insights and guidance on effective approaches for potential buyouts in Q4 and into 2025.

- Factors that strategics prioritize in their acquisition targets
- Areas where Tier 1 companies are making acquisitions
- Characteristics of a successful approach to acquisitions

Participants

Wayne Jarvis - Senior Director BD & Portfolio Strategy, Coloplast

Natalya Shaykevich - Chief Business Development Officer, Halma

Charlie Attlan - SVP, New Business Development, Corporate Strategy & Portfolio, Boston Scientific

Denise Clarke - Director, Strategy & Business Development, Philips Healthcare

Kevin Tahmoush - International Healthcare Executive, Former VP Business Development, BD

Medtech Payoff: The Foundations Of Successful Payer Relationships

09:50 - 10:30 MEDTECH LEADERS

Numerous medtech start-ups face failure due to a lack of alignment with market access principles and insufficient understanding of technology value drivers and future pricing strategies. To address this, a panel of medtech executives will discuss creating value and market adoption tactics for pioneering products, emphasizing direct demonstration of value to payers and providers.

- What does successful implementation truly look
 like
- Listening to the voice of the customer, finding product-market fit.
- · How hospitals are adapting to digital innovations

Participants

Christian Howell - CCO, Cognito Therapeutics

John Milad - CEO, ERS Genomics

Morning Break

10:30 - 11:00 Morning Break

MedTech's Sustainability Ultimatum: Innovate or Perish

11:00 - 11:40 MEDTECH LEADERS

Growing sustainability requirements have created industry-wide and system-level changes in the way the MedTech industry operates. Manufacturers are being held more accountable due to the emerging global EPR (Extended Producer Responsibility) legislation and a renewed global focus on eliminating problematic chemistries and adopting climate-neutral operations. Companies and investors need to adapt this sustainability mindset and implement tactical changes to survive and remain relevant, but no one organization can do it alone.

- The most pressing sustainability issues in the medtech industry
- Upholding sustainability principles to make your medtech innovation competitive and more attractive for funding and implementation
- Business strategies and approaches to meet sustainability goals
- The benefits of collaboration and partnerships (investors & strategics)
- Impending legislation changes and their threat to company growth goals

Participants

Rob Ellsworth - Global Director, Enterprise Sustainability, Medtronic

Sylvain Sachot - Partner, Asabys

Moderator: Jamie Pero Parker - Sustainability Lead, RTI International

Cal St. Denis - Global Director, Sustainabiluty, Johnson and Johnson Medtech

Cash, Crew, and Commercialisation: A Startup's Journey to Success

11:40 - 12:30 MEDTECH LEADERS

Entrepreneurs, investors, and industry partners will share insights on how startups can go beyond technology, emphasizing the importance of capital, people, and strategic partnerships in achieving significant milestones. The panel aims to guide companies in effectively identifying and leveraging these fundamentals for successful development.

- A-Z of fundraising
- Building your team
- Going through the stages of commercialisation
- Finding partners for scale

Participants

Carla Reimold - VP of Industry Strategy & Investments, Massachusetts Life Sciences Center

Ricardo dos Santos - Partner, Head of Venture Studio, Takeda Digital Ventures

SESSIONS

DAY 2 - THURSDAY 12TH SEPTEMBER - 12/09/2024

Connecting Innovators with Strategic Knowledge & Capital
September 11th - 12th, 2024
Hynes Convention Centre, Boston, MA, USA

The Rx for a Successful Exit

12:30 - 13:20 MEDTECH LEADERS

Navigating the unpredictable landscape of medtech doesn't guarantee success, but proactive and strategic steps can enhance your position for potential opportunities. Celebrating a successful exit in the competitive and ever evolving medtech space is undoubtedly rewarding, but achieving it is a challenging journey, given the need to stand out and position for success amidst intense competition. A panel of medtech leaders discuss what it really took to exit

- · Defining your endpoints
- Selecting your team and partners
- · Strategic fundraising approaches
- Navigating common pitfalls for successful exits

Participants

Nate Harrington - Managing Partner, Philips

Maria Shepherd - Executive Board Member, MedExec Women

Giles Hamilton - Operating Partner, New Growth Advisors

Lunch Break

13:20 - 14:20 Networking Break

What Does the 2024 Presidential Election Mean for Patients and Innovation?

14:20 - 15:00 MEDTECH LEADERS

The outcome of the 2024 Presidential Election in the United States has the potential to significantly impact the healthcare and life sciences sector, shaping policies, regulations, and funding priorities for years to come. With broader issues such as healthcare accessibility, affordability, and innovation, the decisions made by the incoming administration will have far-reaching consequences for stakeholders across the industry. This panel discussion seeks to explore the potential implications of the election outcome on the healthcare and life sciences sector, examining key areas of impact and identifying strategies for navigating the evolving landscape.

- Potential impact on drug pricing, approval and insurance
- For medical devices, will stricter regulations create a fallout akin to the MDR in Europe?
- Impact of cyber-security and AI legislation on digital health innovation and implementation

Participants

Maria Shepherd - Executive Board Member, MedExec Women

John Pracyk - SVP, Chief Medical Safety Officer - Global, Olympus Corporation

Haile Dagne - Director, Policy & Reimbursement, GSK

2025 Vision: Navigating Tomorrow's Healthcare and Life Sciences Landscape

15:00 - 15:40 MEDTECH LEADERS

The healthcare industry continues to be a hotbed of innovation and investment, with a diverse range of players in the arena. What future trends are on the horizon and how can the industry continue to move forward as a cohesive sector, play to each others strengths, and ensure we move into 2025 informed and continue to bring proactive and preventative treatments to patients.

- Understanding the evolution of the patient journey
- · Has AI actually delivered for healthcare in 2024?
- How will successful partnerships truly affect the industry – how will patients benefit?
- What future trends can we expect to see and what are the trends we can expect to forget?

Participants

Jennifer Joe - Global Medical Strategy & Population Health Director, AstraZeneca

Stephen Hahn - CEO-Partner, Flagship Pioneering

Ravi Kaushik - VP, Global Head of Device & Digital Innovation & Prod Strategy, Plasma Derived Therapies, Takeda

Emilia Javorksy - Director, Futures Program, Future of Life Institute

Close of Conference

15:40 - 15:45 Networking Break

1

SCHEDULE
DAY 2 – THURSDAY 12TH SEPTEMBER - 12/09/2024

TIME	REGISTRATION & BREAKFAST	MEDTECH LEADERS	MORNING BREAK	NETWORKING BREAK
08:00	08:00 - REGISTRATION & BREAKFAST			
09:00		09:00 - LSX WELCOME ADDRESS		
		09:10 - Bold Moves and Buyouts: The Medtech 2025 M&A Blueprint		
		09:50 - Medtech Payoff: The Foundations Of Successful Payer Relationships		
10:00			10:30 - Morning Break	
11:00		11:00 - MedTech's Sustainability Ultimatum: In- novate or Perish		
		11:40 - Cash, Crew, and Commercialisation: A Startup's Journey to Success		
12:00		12:30 - The Rx for a Successful Exit		
13:00				13:20 - Lunch Break
14:00		14:20 - What Does the 2024 Presidential Election Mean for Patients and Innovation?		
15:00		15:00 - 2025 Vision: Navigating Tomorrow's Healthcare and Life Sciences Landscape		15:40 - Close of Conference